摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-(5-amino-3-tert-butyl-pyrazol-1-yl)-3,4-dihydro-2H-isoquinolin-1-one hydrochloride | 903567-60-2

中文名称
——
中文别名
——
英文名称
7-(5-amino-3-tert-butyl-pyrazol-1-yl)-3,4-dihydro-2H-isoquinolin-1-one hydrochloride
英文别名
7-(5-amino-3-t-butyl-pyrazol-1-yl)-3,4-dihydro-2H-isoquinolin-1-one hydrochloride;7-(5-amino-3-tert-butylpyrazol-1-yl)-3,4-dihydro-2H-isoquinolin-1-one;hydrochloride
7-(5-amino-3-tert-butyl-pyrazol-1-yl)-3,4-dihydro-2H-isoquinolin-1-one hydrochloride化学式
CAS
903567-60-2
化学式
C16H20N4O*ClH
mdl
——
分子量
320.822
InChiKey
HDSGAJHIANGBKD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.46
  • 重原子数:
    22
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    72.9
  • 氢给体数:
    3
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES
    申请人:Flynn L. Daniel
    公开号:US20080090856A1
    公开(公告)日:2008-04-17
    The present invention is concerned with novel compounds useful in the treatment of hyperproliferative diseases and mammalian cancers, especially human cancers. The invention also pertains to methods of modulating kinase activities, pharmaceutical compositions, and methods of treating individuals, incorporating or using the compounds. The preferred compounds are active small molecules set forth in formulae Ia-Iww.
    本发明涉及一种在治疗高增殖性疾病和哺乳动物癌症,尤其是人类癌症方面有用的新化合物。该发明还涉及调节激酶活性的方法、药物组合物以及治疗个体的方法,包括或使用这些化合物。优选的化合物是在公式Ia-Iww中列出的活性小分子。
  • Enzyme modulators and treatments
    申请人:Flynn L. Daniel
    公开号:US20070078121A1
    公开(公告)日:2007-04-05
    Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, immunological disorders, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of kinases, including p38 kinase protein, abl kinase protein, bcr-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein, comprises the step of contacting said kinase protein with the novel compounds.
    提供了新型化合物及其使用方法,用于治疗炎症性疾病、免疫性疾病、过度增生性疾病、癌症以及以高血管化为特征的疾病。在一种优选实施方式中,调节激酶的激活状态,包括p38激酶蛋白、abl激酶蛋白、bcr-abl激酶蛋白、braf激酶蛋白、VEGFR激酶蛋白或PDGFR激酶蛋白,包括将该激酶蛋白与新型化合物接触的步骤。
  • ENZYME MODULATORS AND TREATMENTS
    申请人:Flynn L. Daniel
    公开号:US20080113967A1
    公开(公告)日:2008-05-15
    Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein, abl kinase protein, ber-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein comprises the step of contacting said kinase protein with the novel compounds.
    本发明提供了新的化合物及其使用方法,用于治疗炎症状况、过度增殖性疾病、癌症和以高血管化为特征的疾病。在优选实施例中,调节p38激酶蛋白、abl激酶蛋白、ber-abl激酶蛋白、braf激酶蛋白、VEGFR激酶蛋白或PDGFR激酶蛋白的激活状态,包括将该激酶蛋白与新的化合物接触的步骤。
  • Anti-inflammatory medicaments
    申请人:Flynn L. Daniel
    公开号:US20070191336A1
    公开(公告)日:2007-08-16
    Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.
    提供了治疗炎症状况的新化合物和使用这些化合物的方法。在一个优选实施例中,调节p38激酶蛋白的激活状态包括将激酶蛋白与新的化合物接触的步骤。
  • ANTI-INFLAMMATORY MEDICAMENTS
    申请人:Flynn Daniel L.
    公开号:US20090312349A1
    公开(公告)日:2009-12-17
    Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein, abl kinase protein, bcr-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein comprises the step of contacting said kinase protein with the novel compounds.
    本发明提供了新型化合物及其使用方法,用于治疗炎症状况、过度增殖性疾病、癌症和以高血管化为特征的疾病。在一个优选实施例中,调节p38激酶蛋白、abl激酶蛋白、bcr-abl激酶蛋白、braf激酶蛋白、VEGFR激酶蛋白或PDGFR激酶蛋白的活化状态包括将该激酶蛋白与新型化合物接触的步骤。
查看更多